Clinical trial
Risedronate in Osteopenic Postmenopausal Women
NCT00345644 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00345644 |
|---|---|
| Title | Risedronate in Osteopenic Postmenopausal Women |
| Official title | A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo |
| Acronym | OSMAUSE |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | risedronate, risedronate placebo |
| Enrollment | 156 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jun 28, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: